Comparison of Thromboembolism Outcomes in Patients with Sickle Cell Disease Prescribed Hormonal Contraception

Overview

Journal Blood Adv

Specialty Hematology

Date 2023 Aug 16

PMID 37585480

Authors

Natasha S Bala

Joseph R Stanek

Sara K Vesely

Robert M Cronin

Susan E Creary

Andrea H Roe

Wendy Xu

Sarah H OBrien

Affiliations

Soon will be listed here.

Abstract

Patients with sickle cell disease (SCD) are at a risk of thromboembolism (TE), and use of hormonal contraception can further increase that risk. This study aims to assess patterns of hormonal contraceptive use and compare risk of contraception-related TE between combined hormonal contraceptives (CHCs) and progestin-only contraceptives (POCs). Patients with SCD aged between 12 and 44 years with a new prescription of a hormonal contraceptive in the Centers for Medicare and Medicaid Services Medicaid Analytic eXtract database (2006-2018) were followed up to 1 year. We identified 7173 new users: 44.6% initiated CHC and 55.4% initiated POC. Combined oral contraceptive pills (OCPs; 36.5%) and progestin-only depot medroxyprogesterone acetate (33.9%) were the most frequently prescribed agents. A total of 1.8% of contraception users had a new diagnosis of TE within 1 year of the first identified contraception prescription. There were no significant differences in TE event rates between CHC and POC users (17.2 and 24.7 events per 1000 person-years, respectively). In patients prescribed OCP, there were no differences in TE event rates based on estrogen dose or progestin generation. Transdermal patch had a 2.4-fold increased risk of TE as compared with that of OCP. Although limited by the retrospective study design and use of administrative claims data, this study found no significant differences in TE rates between new users of CHC and POC in patients with SCD. Careful evaluation of underlying TE risk factors should be considered for each patient with SCD before initiation of hormonal contraception.

Citing Articles

Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.

Light J, Abrams C, Ilich A, Huang S, Zhu H, Baskin-Miller J Res Pract Thromb Haemost. 2024; 8(4):102471.

PMID: 39099800 PMC: 11295566. DOI: 10.1016/j.rpth.2024.102471.

References

Lidegaard O, Lokkegaard E, Svendsen A, Agger C . Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 339:b2890. PMC: 2726928. DOI: 10.1136/bmj.b2890. View

Smith-Whitley K . Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):359-366. PMC: 6913482. DOI: 10.1182/hematology.2019000039. View

Cole J, Norman H, Doherty M, Walker A . Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007; 109(2 Pt 1):339-46. DOI: 10.1097/01.AOG.0000250968.82370.04. View

Daniels K, Abma J . Current Contraceptive Status Among Women Aged 15-49: United States, 2017-2019. NCHS Data Brief. 2020; (388):1-8. View

Scholes D, LaCroix A, Ichikawa L, Barlow W, Ott S . Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002; 13(5):581-7. DOI: 10.1097/00001648-200209000-00015. View

Barfield W, Barradas D, Manning S, Kotelchuck M, Shapiro-Mendoza C . Sickle cell disease and pregnancy outcomes: women of African descent. Am J Prev Med. 2010; 38(4 Suppl):S542-9. DOI: 10.1016/j.amepre.2009.12.020. View

Eissa A, Tuck S, Rantell K, Stott D . Trends in family planning and counselling for women with sickle cell disease in the UK over two decades. J Fam Plann Reprod Health Care. 2014; 41(2):96-101. DOI: 10.1136/jfprhc-2013-100763. View

Snyder A, Lane P, Zhou M, Paulukonis S, Hulihan M . The accuracy of hospital ICD-9-CM codes for determining Sickle Cell Disease genotype. J Rare Dis Res Treat. 2017; 2(4):39-45. PMC: 5709815. View

Huo J, Yang M, Shih Y . Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful Use. Value Health. 2018; 21(3):334-340. DOI: 10.1016/j.jval.2017.09.002. View

10.

Berenson A, Rahman M, Breitkopf C, Bi L . Effects of depot medroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet Gynecol. 2008; 112(4):788-99. PMC: 2745348. DOI: 10.1097/AOG.0b013e3181875b78. View

11.

Day M, Stimpson S, Rodeghier M, Ghafuri D, Callaghan M, Zaidi A . Contraceptive Methods and the Impact of Menstruation on Daily Functioning in Women with Sickle Cell Disease. South Med J. 2019; 112(3):174-179. DOI: 10.14423/SMJ.0000000000000949. View

12.

Eisenbrown K, Nimmer M, Brousseau D . The accuracy of using ICD-9-CM codes to determine genotype and fever status of patients with sickle cell disease. Pediatr Blood Cancer. 2015; 62(5):924-5. DOI: 10.1002/pbc.25432. View

13.

Bae E, Tangel V, Liu N, Abramovitz S, White R . Inpatient mortality and postpartum readmission rates in sickle cell disease pregnancies: a multistate analysis, 2007-2014. J Matern Fetal Neonatal Med. 2019; 34(17):2783-2792. DOI: 10.1080/14767058.2019.1671333. View

14.

Brunson A, Lei A, Rosenberg A, White R, Keegan T, Wun T . Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017; 178(2):319-326. DOI: 10.1111/bjh.14655. View

15.

Yawn B, Buchanan G, Afenyi-Annan A, Ballas S, Hassell K, James A . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-48. DOI: 10.1001/jama.2014.10517. View

16.

Tepper N, Whiteman M, Marchbanks P, James A, Curtis K . Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016; 94(6):678-700. PMC: 11034842. DOI: 10.1016/j.contraception.2016.04.014. View

17.

Early M, Eke A, Gemmill A, Lanzkron S, Pecker L . Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018. JAMA Netw Open. 2023; 6(2):e2254552. PMC: 9896307. DOI: 10.1001/jamanetworkopen.2022.54552. View

18.

Bergendal A, Persson I, Odeberg J, Sundstrom A, Holmstrom M, Schulman S . Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. 2014; 124(3):600-609. DOI: 10.1097/AOG.0000000000000411. View

19.

Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M . Oral Contraceptives and HRT Risk of Thrombosis. Clin Appl Thromb Hemost. 2017; 24(2):217-225. PMC: 6714678. DOI: 10.1177/1076029616683802. View

20.

Haddad L, Curtis K, Legardy-Williams J, Cwiak C, Jamieson D . Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception. 2011; 85(6):527-37. DOI: 10.1016/j.contraception.2011.10.008. View